Who are Maintenance weekly x4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, Blincyto, BLINATUMOMAB, MONJUVI, UPLIZNA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/maintenance-weekly-x4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Maintenance weekly x4 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maintenance weekly x4 (Maintenance weekly x4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 3 Monoclonal antibody CD19 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Maintenance weekly x4 (Maintenance weekly x4) — Fondazione Italiana Linfomi - ETS. This drug targets the CD19 protein on B cells to induce apoptosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maintenance weekly x4 TARGET	Maintenance weekly x4	Fondazione Italiana Linfomi - ETS	phase 3	Monoclonal antibody	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC	marketed		B-lymphocyte antigen CD19
UPLIZNA	INEBILIZUMAB-CDON	VIELA BIO	marketed	CD19-directed Cytolytic Antibody [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, B-lymphocyte antigen CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maintenance weekly x4 — Competitive Intelligence Brief. https://druglandscape.com/ci/maintenance-weekly-x4. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing